The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Safety and activity of ceralasertib in the treatment of MDS
Andrew M. Brunner, MD, Massachusetts General Hospital, Boston, MA, shares some insights into the safety and preliminary activity of ceralasertib, an ATR kinase inhibitor, in the treatment of patients with myelodysplastic syndromes (MDS). Patients with MDS often have a poor survival outcome and limited therapeutic options after they stop responding to azacitidine and decitabine, and Dr Brunner explains that splicing factor mutation also contributes to this disease. Dr Brunner then gives an overview of this mutation and the role of ATR kinase, and further explains the mechanism of action of ceralasertib. To conclude, Dr Brunner summarizes some results from this study, including the side effects and clinical activity observed in patients treated with ceralasertib, and how this agent may play an important role in the future of MDS treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Keros Therapeutics: Consultancy; AstraZeneca: Research Funding; GSK: Research Funding; Aprea: Research Funding; Agios: Consultancy; Acceleron: Consultancy; Janssen: Research Funding; Takeda: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.
